Cargando…

Prognostic Value of Serum Free Light Chains Measurements in Multiple Myeloma Patients

BACKGROUND: The outcome for patients with Multiple Myeloma (MM) is highly variable, therefore, the existence of robust and easy to determine prognostic markers is extremely important for an efficient management of these patients. Presently, there is a debate about the role of the serum free light ch...

Descripción completa

Detalles Bibliográficos
Autores principales:	García de Veas Silva, José Luis, Bermudo Guitarte, Carmen, Menéndez Valladares, Paloma, Rojas Noboa, Johanna Carolina, Kestler, Krysta, Duro Millán, Rafael
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2016
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5125636/ https://www.ncbi.nlm.nih.gov/pubmed/27893836 http://dx.doi.org/10.1371/journal.pone.0166841

Ejemplares similares

Free kappa light chains in cerebrospinal fluid as a biomarker to assess risk conversion to multiple sclerosis
por: Menéndez-Valladares, P, et al.
Publicado: (2015)

HLC Pair Suppression as a Risk Factor for Bacterial Bloodstream Infections and Early Mortality in Newly Diagnosed Intact Immunoglobulin Multiple Myeloma Patients
por: Garcia de Veas Silva, Jose Luis, et al.
Publicado: (2021)

Light chain myeloma and detection of free light chains in serum and urine of dogs and cats
por: Harris, Robert Adam, et al.
Publicado: (2021)

Multiple myeloma: Detection of free monoclonal light chains by modified immunofixation electrophoresis with antisera against free light chains
por: Wilhite, Dorian, et al.
Publicado: (2021)

Comparison of two free light chain assays: performance of the involved free light chain ratio and implications for diagnosis of multiple myeloma
por: Willrich, Maria Alice V., et al.
Publicado: (2022)

Serum Free Light Chain Only Myeloma with Cytoplasmic IgM
por: Ebana, Hideaki, et al.
Publicado: (2014)

Serum free light chains and multiple myeloma: Is it time to extend their application?
por: Markovic, Uros, et al.
Publicado: (2020)

Can urine studies be replaced by serum free light chains measurements to assign responses in multiple myeloma patients?
por: Cárdenas, Maria Cruz, et al.
Publicado: (2022)

Prognostic utility of serum free light chain ratios and heavy-light chain ratios in multiple myeloma in three PETHEMA/GEM phase III clinical trials
por: Lopez-Anglada, Lucia, et al.
Publicado: (2018)

The Current Role of the Heavy/Light Chain Assay in the Diagnosis, Prognosis and Monitoring of Multiple Myeloma: An Evidence-Based Approach
por: Ríos-Tamayo, Rafael, et al.
Publicado: (2021)

Role of serum‐free light chain assay for defining response and progression in immunoglobulin secretory multiple myeloma
por: Tacchetti, Paola, et al.
Publicado: (2022)

Serum free light chain levels and renal function at diagnosis in patients with multiple myeloma
por: Yadav, Punit, et al.
Publicado: (2018)

Early Normalization of Free Light Chains Predicts Better Outcomes in Patients with Multiple Myeloma
por: Benson, Rony, et al.
Publicado: (2020)

Light Chain Myeloma Precipitating Cryoglobulinemic Vasculitis
por: Saeed, Bilal, et al.
Publicado: (2023)

Serum free light chain measurement aids the diagnosis of myeloma in patients with severe renal failure
por: Hutchison, Colin A, et al.
Publicado: (2008)

Responses in multiple myeloma should be assigned according to serum, not urine, free light chain measurements
por: Dejoie, Thomas, et al.
Publicado: (2018)

Serum free light chain level at diagnosis in myeloma cast nephropathy—a multicentre study
por: Yadav, Punit, et al.
Publicado: (2020)

INDEPENDENT SYNTHESIS OF LIGHT AND HEAVY CHAINS : Quantitation of Light-Chain Production by Mouse Myeloma Variants
por: Laskov, Reuven, et al.
Publicado: (1974)

Utility of Serum Free Light Chain Measurements in Multiple Myeloma Patients Not Achieving Complete Response to Therapy
por: Moustafa, Muhamad Alhaj, et al.
Publicado: (2015)

Hemodiafiltration with ultrafiltrate regeneration reduces free light chains without albumin loss in multiple myeloma patients
por: Pendón-Ruiz de Mier, M. Victoria, et al.
Publicado: (2020)

Light-Chain Multiple Myeloma: A Diagnostic Challenge
por: Silva, Cristina, et al.
Publicado: (2021)

Crystalline light chain cast nephropathy in multiple myeloma
por: Lin, Zi-Shan, et al.
Publicado: (2021)

Multiple myeloma with acute light chain cast nephropathy
por: Leung, Nelson, et al.
Publicado: (2023)

Diagnostic accuracy of monoclonal antibody based serum immunoglobulin free light chain immunoassays in myeloma cast nephropathy
por: Hutchison, Colin A, et al.
Publicado: (2012)

Combination of bortezomib-based chemotherapy and extracorporeal free light chain removal for treating cast nephropathy in multiple myeloma
por: Bachmann, Ulrike, et al.
Publicado: (2008)

Comparison of three different serum-free light-chain assays—implications on diagnostic and therapeutic monitoring of multiple myeloma
por: Schieferdecker, Aneta, et al.
Publicado: (2020)

Early free light chain reduction following treatment initiation predicts favorable outcome in intact immunoglobulin myeloma
por: Claveau, Jean-Sébastien, et al.
Publicado: (2022)

Evaluation of Correlation between Serum Free Light-Chain Assay and Bone Marrow Study in Multiple Myeloma Patients
por: Zamani, Fatemeh, et al.
Publicado: (2021)

Impacts of the COVID-19 Pandemic on Assessment of M-Protein and Free Light Chain Levels in Patients with Multiple Myeloma
por: Roose, James, et al.
Publicado: (2022)

Fibrillary inclusions in light chain proximal tubulopathy associated with myeloma
por: Neild, G. H., et al.
Publicado: (2012)

Cerebellar ataxia and sensory ganglionopathy associated with light-chain myeloma
por: Zis, Panagiotis, et al.
Publicado: (2017)

Myosin light-chain phosphatase regulates basal actomyosin oscillations during morphogenesis
por: Valencia-Expósito, Andrea, et al.
Publicado: (2016)

The clinical utility of serum free light chain and heavy/light chain assays in monitoring disease activity in patients with IgG myeloma after achieving a deep response
por: Shimizu, Kazuyuki, et al.
Publicado: (2017)

Removal of free light chains in hemodialysis patients without multiple myeloma: a crossover comparison of three different dialyzers
por: Donati, Gabriele, et al.
Publicado: (2016)

A method to obtain purified free light chain monomers and dimers from urine samples of patients with multiple myeloma
por: Caponi, Laura, et al.
Publicado: (2022)

Follow-up of IgD-κ multiple myeloma by monitoring free light chains and total heavy chain IgD: A case report
por: De Santis, Elena, et al.
Publicado: (2016)

Serum Free Light-Chain Ratio at Diagnosis Is Associated with Early Renal Damage in Multiple Myeloma: A Case Series Real-World Study
por: De Novellis, Danilo, et al.
Publicado: (2022)

Value of antibodies to free light chains in immunoperoxidase studies of renal biopsies
por: Owen-Casey, Mared P, et al.
Publicado: (2014)

Incidence and clinical characteristics of multiple myeloma with low M-protein levels and normal values of hemoglobin, creatinine, calcium, and serum free light chain ratio
por: Szabo, Agoston Gyula, et al.
Publicado: (2021)

Triphenotypic multiple myeloma expressing kappa or lambda light chain or both
por: Liu, Yang, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_k0cj9rvs07oipkthat2t3ra5cd